Population Exposure–response Analysis of Cabozantinib Efficacy and Safety Endpoints in Patients with Renal Cell Carcinoma
Cancer chemotherapy and pharmacology(2018)
摘要
In the phase III METEOR trial, tyrosine kinase inhibitor cabozantinib significantly improved progression-free survival (PFS), objective response rate (ORR), and overall survival compared to everolimus in patients with advanced renal cell carcinoma (RCC) who had received prior VEGFR inhibitor therapy. In METEOR, RCC patients started at a daily 60-mg cabozantinib tablet (Cabometyx™) dose but could reduce to 40- or 20-mg to achieve a tolerated exposure.
更多查看译文
关键词
Cabozantinib,Exposure–response modeling,Renal cell carcinoma
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要